{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-095054","form_type":"8-K","ticker":"LXEO","cik":"0001907108","company_name":"Lexeo Therapeutics, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.174534+00:00","generated_at":"2026-05-31T10:09:59.608371+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lexeo Q2 net loss $21.2M; positive interim gene therapy data in FA cardiomyopathy","bullets":["Net loss of $21.2M ($0.64 per share) vs $13.4M ($8.30) year ago; R&D $16.6M, G&A $7.0M.","Cash $175M expected to fund operations into 2027.","LX2006 for FA cardiomyopathy showed no treatment-related serious adverse events; FDA engagement for registrational study surrogate endpoints initiated.","Phase 1/2 trial for LX2020 (PKP2-ACM) recruiting; Cohort 1 data update on track for 2H 2024.","Tim Van Hauwermeiren (co-founder/CEO argenx) appointed to Board in July 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-095054","json":"https://secwatch.observer/filing/0000950170-24-095054.json","markdown":"https://secwatch.observer/filing/0000950170-24-095054.md","text":"https://secwatch.observer/filing/0000950170-24-095054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024095054/0000950170-24-095054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024095054/lxeo-20240812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:09:59.608371+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}